Rusan Pharma Invests ₹300 Crore in New API Manufacturing Plant in Madhya Pradesh

Screenshot 2023 11 27 133739

Rusan Pharma Ltd., a global player in pain management and deaddiction solutions, has unveiled plans for its second Active Pharmaceutical Ingredient (API) manufacturing facility in the Pithampur Special Economic Zone (SEZ) in Madhya Pradesh. The company is set to invest ₹300 crore in two phases to make the plant operational, with the first phase expected to commence operations in January 2024.

Navin Saxena, Founder and Chairman of Rusan Pharma, highlighted the significance of the new API manufacturing facility, stating, “The new API facility will enable us to significantly enhance our existing API capacity and ensure the security of supply of critical APIs to meet the growing demand for our addiction treatment and pain management products in India and globally.” Dr. Saxena emphasized the company’s commitment to making addiction treatment accessible and acceptable, considering quality healthcare as a right for everyone.

The strategic location of the new facility in the Pithampur SEZ leverages support and subsidies provided by the Madhya Pradesh state government. This central location is expected to streamline business operations and export processes through the dry port, aligning perfectly with Rusan Pharma’s expansion plans.

Kunal Saxena, Managing Director of Rusan Pharma, outlined the investment of ₹300 crore in two phases, aiming to increase the API manufacturing capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur. The new plant features five modular API manufacturing blocks with dedicated suites for finished API manufacturing, providing complete control over product quality and reducing dependency on imports.

Saxena highlighted the incorporation of advanced automation and compliant software, moving towards paperless manufacturing and stringent environmental controls. This approach will enhance the affordability of essential medicines, aligning with the company’s commitment to excellence.

Rusan Pharma’s current Good Manufacturing Practice (GMP) approvals for its APIs and finished formulations facilities position it to cater to 90% of the world’s demand. The facility is designed to meet stringent international regulatory guidelines, ensuring the highest level of compliance. With an annual production capability of 400 metric tonnes of APIs, the new facility contributes significantly to Rusan Pharma’s growth and expansion plans, diversifying its portfolio and expanding its reach in India and other global markets.

Benjamin Turner

Benjamin Turner is a journalism graduate with keen interest in covering Technology news – specifically wall street business. He has as a keen eye for technologies and has predicted quite a few successful startups over the last couple of years. Benjamin goal with this website is to report accurately on all kinds of stock news, and have a great deal of passion for Technology news reporting. Benjamin is diligent and proactive when it comes to Technology news reporting.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post
Screenshot 2023 11 27 132500

Binance Faces Severe Penalties as CEO Pleads Guilty to Criminal Activity

Next Post
Screenshot 2023 11 27 135432

Foreign Portfolio Investors (FPIs) Reverse Selling Trend, Inject ₹378 Crore into Equities in November

Related Posts